These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 23625743)

  • 1. New activities for the anti-tumor agent trabectedin: taking two birds with one stone.
    D'Incalci M; Frapolli R; Germano G; Allavena P
    Oncotarget; 2013 Apr; 4(4):496-7. PubMed ID: 23625743
    [No Abstract]   [Full Text] [Related]  

  • 2. Trabectedin, a drug acting on both cancer cells and the tumour microenvironment.
    D'Incalci M; Badri N; Galmarini CM; Allavena P
    Br J Cancer; 2014 Aug; 111(4):646-50. PubMed ID: 24755886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trabectedin and plitidepsin: drugs from the sea that strike the tumor microenvironment.
    Galmarini CM; D'Incalci M; Allavena P
    Mar Drugs; 2014 Jan; 12(2):719-33. PubMed ID: 24473171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trabectedin mechanism of action: what's new?
    D'Incalci M
    Future Oncol; 2013 Dec; 9(12 Suppl):5-10. PubMed ID: 24195524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biology of ovarian cancer and trabectedin mechanism of action.
    Ray-Coquard I
    Future Oncol; 2013 Dec; 9(12 Suppl):11-7. PubMed ID: 24195525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trabectedin for the treatment of breast cancer.
    D'Incalci M; Zambelli A
    Expert Opin Investig Drugs; 2016; 25(1):105-15. PubMed ID: 26592307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trabectedin mechanism of action and platinum resistance: molecular rationale.
    Ray-Coquard I
    Future Oncol; 2017 Oct; 13(23s):17-21. PubMed ID: 29020822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
    Guo Z; Wang H; Meng F; Li J; Zhang S
    J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitory effects of marine-derived DNA-binding anti-tumour tetrahydroisoquinolines on the Fanconi anaemia pathway.
    Martínez S; Pérez L; Galmarini CM; Aracil M; Tercero JC; Gago F; Albella B; Bueren JA
    Br J Pharmacol; 2013 Oct; 170(4):871-82. PubMed ID: 23937566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RG7112, a small-molecule inhibitor of MDM2, enhances trabectedin response in soft tissue sarcomas.
    Obrador-Hevia A; Martinez-Font E; Felipe-Abrio I; Calabuig-Fariñas S; Serra-Sitjar M; López-Guerrero JA; Ramos R; Alemany R; Martín-Broto J
    Cancer Invest; 2015; 33(9):440-50. PubMed ID: 26288114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The activity of trabectedin as a single agent or in combination with everolimus for clear cell carcinoma of the ovary.
    Mabuchi S; Hisamatsu T; Kawase C; Hayashi M; Sawada K; Mimura K; Takahashi K; Takahashi T; Kurachi H; Kimura T
    Clin Cancer Res; 2011 Jul; 17(13):4462-73. PubMed ID: 21622721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unique features of trabectedin mechanism of action.
    Larsen AK; Galmarini CM; D'Incalci M
    Cancer Chemother Pharmacol; 2016 Apr; 77(4):663-71. PubMed ID: 26666647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of trabectedin (ET-743): a unique mechanism of action.
    D'Incalci M; Galmarini CM
    Mol Cancer Ther; 2010 Aug; 9(8):2157-63. PubMed ID: 20647340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedin.
    Colmegna B; Uboldi S; Frapolli R; Licandro SA; Panini N; Galmarini CM; Badri N; Spanswick VJ; Bingham JP; Kiakos K; Erba E; Hartley JA; D'Incalci M
    Br J Cancer; 2015 Dec; 113(12):1687-93. PubMed ID: 26633559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The intriguing patterns of tumor response to trabectedin.
    Sanfilippo R; Casali PG
    Expert Rev Anticancer Ther; 2013 Jun; 13(6 Suppl 1):21-4. PubMed ID: 23638727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trabectedin is a promising antitumour agent for synovial sarcoma.
    Yasui H; Imura Y; Outani H; Hamada K; Nakai T; Yamada S; Takenaka S; Sasagawa S; Araki N; Itoh K; Myoui A; Yoshikawa H; Naka N
    J Chemother; 2016 Oct; 28(5):417-24. PubMed ID: 27077926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition In Vitro.
    Hoda MA; Pirker C; Dong Y; Schelch K; Heffeter P; Kryeziu K; van Schoonhoven S; Klikovits T; Laszlo V; Rozsas A; Ozsvar J; Klepetko W; Döme B; Grusch M; Hegedüs B; Berger W
    Mol Cancer Ther; 2016 Oct; 15(10):2357-2369. PubMed ID: 27512118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trabectedin (ET-743): evaluation of its use in advanced soft-tissue sarcoma.
    Schöffski P; Wolter P; Clement P; Sciot R; De Wever I; Wozniak A; Stefan C; Dumez H
    Future Oncol; 2007 Aug; 3(4):381-92. PubMed ID: 17661712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Some hope from marine natural products.
    D'Incalci M
    Ann Oncol; 1998 Sep; 9(9):937-8. PubMed ID: 9818065
    [No Abstract]   [Full Text] [Related]  

  • 20. Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors.
    Forni C; Minuzzo M; Virdis E; Tamborini E; Simone M; Tavecchio M; Erba E; Grosso F; Gronchi A; Aman P; Casali P; D'Incalci M; Pilotti S; Mantovani R
    Mol Cancer Ther; 2009 Feb; 8(2):449-57. PubMed ID: 19190116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.